Short Interest in Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Expands By 31.6%

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 427,713 shares, a growth of 31.6% from the February 26th total of 325,076 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 220,622 shares, the days-to-cover ratio is presently 1.9 days.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth approximately $76,000. Virtu Financial LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $49,000. Connective Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $100,000. Sigma Planning Corp acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $334,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $266,000. Institutional investors own 14.20% of the company’s stock.

Analyst Upgrades and Downgrades

DMRA has been the subject of a number of research analyst reports. UBS Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They issued a “buy” rating and a $45.00 target price for the company. Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday. They set an “outperform” rating and a $46.00 price target on the stock. Wall Street Zen upgraded Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, December 29th. Finally, Leerink Partners assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, January 7th. They set an “outperform” rating and a $46.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.25.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of NASDAQ DMRA traded down $0.13 during trading on Friday, reaching $25.50. The company had a trading volume of 171,777 shares, compared to its average volume of 292,469. Damora Therapeutics, Inc. Common Stock has a 52 week low of $2.01 and a 52 week high of $38.33. The business’s 50 day moving average price is $27.02 and its 200-day moving average price is $19.77. The stock has a market cap of $1.54 billion, a PE ratio of -2.11 and a beta of 1.42.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.